Hi to all, I keep wondering about this . . . please help if you can. Where flow cytometry indicates a CD20 dimly positive population on a lymphoma (i.e., CLL) do you see a positive therapeutic effect? Apparently the answer is yes. What about when you have a CD20-negative lymphoma (i.e. diffuse large cell, B cell) that is positive by immunohistochemical staining with L26? It seems to me there there is no _surface_ antigen for the mAb to bind, so that the value of Rituxan in this situation is questionable. Or is it that the mAb is internalized somehow and then can bind up the CD20 sites? Or a try-it-and-see approach? Please pass along any references I've missed or experiences you've had with this. Thanks! sharon --- Sharon F. Vogt MT(ASCP) Pathology Dept. Dekalb Medical Center 2701 N. Decatur Road Decatur, GA 30033 404-501-5253 404-297-0444 fax
This archive was generated by hypermail 2b29 : Wed Apr 03 2002 - 11:56:06 EST